Results 51 to 60 of about 7,789 (204)

Treatment of Discoid Lupus Erythematosus with Upadacitinib: A Case Report

Clinical, Cosmetic and Investigational Dermatology, 2023
Wenting Hu, Si Zhang, Cuihong Lian Department of Dermatology, Shenzhen Second People’s Hospital, Shenzhen, Guangdong, People’s Republic of ChinaCorrespondence: Cuihong Lian, Department of Dermatology, Shenzhen Second People’s Hospital, No.
Hu W, Zhang S, Lian C
doaj  

Long-term safety and efficacy of upadacitinib in Japanese patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: 5-year results from the SELECT-SUNRISE randomised controlled trial

RMD Open
Objective To assess the long-term safety and efficacy of upadacitinib over 5 years in Japanese patients with moderate-to-severe active rheumatoid arthritis and an inadequate response to stable doses of conventional synthetic disease-modifying ...
Tsutomu Takeuchi, Hideto Kameda, Yoshiya Tanaka, Mitsuhiro Kawano, Motohiro Oribe, Kunihiro Yamaoka, Heidi S Camp, Yuko Konishi, Sumi Chonan, Kimitoshi Ikeda   +9 more
doaj   +1 more source

Update on Non‐Biological and RNA‐Based Therapeutics in Chronic Inflammatory Diseases: Precision Medicine Through Small Molecules: An EAACI Position Paper

Allergy, EarlyView.
ABSTRACT In the last decades, critical advancements in research technology and knowledge on disease mechanisms steered therapeutic approaches for chronic inflammatory diseases towards unprecedented target specificity. For allergic and chronic lung diseases, biologic drugs pioneered this goal, acquiring on the way—through the clinical use of monoclonal ...
F. Roth‐Walter, I. M. Adcock, C. Benito‐Villalvilla, R. Bianchini, L. Bjermer, G. Caramori, L. Cari, K. F. Chung, Z. Diamant, I. Eguiluz‐Gracia, E. F. Knol, M. Jesenak, F. Levi‐Schaffer, G. Nocentini, L. O'Mahony, O. Palomares, F. Redegeld, M. Sokolowska, B. Van Esch, M. Zurlo, C. Stellato   +20 more
wiley   +1 more source

Total eosinophil count as a biomarker for therapeutic effects of upadacitinib in atopic dermatitis over 48 weeks

Frontiers in Immunology
BackgroundAtopic dermatitis (AD) is a chronic skin disease characterized by type 2-skewed immune responses, and significantly influenced by cytokines dependent on Janus kinases (JAKs).
Teppei Hagino, Risa Hamada, Mai Yoshida, Eita Fujimoto, Hidehisa Saeki, Naoko Kanda   +5 more
doaj   +1 more source

Against Moral Panic and Citation Fiction: A Critique of “Panem, Corticoids and Circenses” and a Proposal for Editorial Gatekeeping on Reference Integrity

Bioethics, EarlyView.
ABSTRACT The proposed Enhanced Games have become a convenient stage for bioethical sermonising about risk, authenticity, and the “spirit of sport”. This is epitomized by a recent article arguing that institutionalizing pharmacological enhancement under the “pretence of medical supervision and personal autonomy” would redefine human excellence in ...
Ognjen Arandjelović
wiley   +1 more source

Upadacitinib in active non-radiographic axial spondyloarthritis: 2-year data from the phase 3 SELECT-AXIS 2 study

Arthritis Research & Therapy
Background In SELECT-AXIS 2, upadacitinib improved the signs and symptoms of active non-radiographic axial spondyloarthritis (nr-axSpA) through 52 weeks versus placebo and was well tolerated.
Filip Van den Bosch, Atul Deodhar, Denis Poddubnyy, Walter P. Maksymowych, Désirée van der Heijde, Tae-Hwan Kim, Mitsumasa Kishimoto, Xenofon Baraliakos, Xianwei Bu, Ivan Lagunes-Galindo, In-Ho Song, Peter Wung, Koji Kato, Anna Shmagel   +13 more
doaj   +1 more source

Development of an UPLC-MS/MS Method for the Quantitative Analysis of Upadacitinib in Beagle Dog Plasma and Pharmacokinetics Study

Drug Design, Development and Therapy, 2021
Meng-Jie Wang,1 Yu-Hang Zhao,2 Chen Fan,3 Ying-Jie Wang,3 Xin-Qi Wang,3 Xiang-Jun Qiu,3 Rui-Le Shen1 1Department of Neurology, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, Henan ...
Wang MJ, Zhao YH, Fan C, Wang YJ, Wang XQ, Qiu XJ, Shen RL   +6 more
doaj  

Achieving Optimal Treatment Targets and Minimal Disease Activity with Upadacitinib for Moderate-to-Severe Atopic Dermatitis: Integrated Analysis of Phase 3 Studies (Measure Up 1 and 2)

Dermatology and Therapy
Introduction The Aiming High in Eczema/Atopic Dermatitis (AHEAD) guidelines recommend achieving minimal disease activity (MDA) in atopic dermatitis (AD), defined as simultaneous achievement of optimal treatment targets for at least one clinician- and one
Jonathan I. Silverberg, Melinda Gooderham, Norito Katoh, Valeria Aoki, Andrew E. Pink, Yousef Binamer, Brad Glick, Petra Staubach, Brian Calimlim, Chao Li, Ayman Grada, Alvaro Moreira, Wan-Ju Lee, Andreas Wollenberg   +13 more
doaj   +1 more source

A Case of Refractory Vernal Keratoconjunctivitis Showing Improvement after the Administration of Upadacitinib for the Treatment of Atopic Dermatitis

Diagnostics
Vernal keratoconjunctivitis is a persistent allergic ocular disease predominantly mediated by the T-helper 2 lymphocyte-associated immune response. The standard therapeutic approaches for vernal keratoconjunctivitis include topical corticosteroids and ...
Yoshihito Mima, Eri Tsutsumi, Tsutomu Ohtsuka, Ippei Ebato, Yukihiro Nakata, Taro Kubota, Yuta Norimatsu   +6 more
doaj   +1 more source

Treatment with Upadacitinib in Active Psoriatic Arthritis: Efficacy and Safety Data of the First 192 Patients from the UPJOINT Study, a Multicentre, Observational Study in Clinical Practice [PDF]

, 2023
S. G. Werner, Xenofon Baraliakos, Sabine Reckert, M. Bohl-Bühler, Marie-Claude Laliberté, Tanya Girard, Katharina Jeromin, Nikola Baschuk, Björn Fritz, Louis Bessette, Axel J. Hueber   +10 more
openalex   +1 more source